Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

ClinicalTrials.gov ID: NCT01180790

Public ClinicalTrials.gov record NCT01180790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Participants With Chronic Hepatitis C Virus Genotype 1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.

Study identification

NCT ID: NCT01180790
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 122 participants

Conditions and interventions

Conditions

Hepatitis C

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2010 (Type not available)
Primary completion: Mar 2012 (Actual)
Completion: Apr 2013 (Actual)
Last update posted: Aug 30, 2023

2010 – 2013

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Clinical Trial Site	Los Angeles	California	90036	—
Clinical Trial Site	Los Angeles	California	90048	—
Clinical Trial Site	San Francisco	California	94115	—
Clinical Trial Site	Bradenton	Florida	34209	—
Clinical Trial Site	Orlando	Florida	32803	—
Clinical Trial Site	Chicago	Illinois	60611	—
Clinical Trial Site	Overland Park	Kansas	66211	—
Clinical Trial Site	St Louis	Missouri	63104	—
Clinical Trial Site	Las Vegas	Nevada	89106	—
Clinical Trial Site	New York	New York	10065	—
Clinical Trial Site	Philadelphia	Pennsylvania	19141	—
Clinical Trial Site	Arlington	Texas	76012	—
Clinical Trial Site	San Antonio	Texas	78215	—
Clinical Trial Site	Newport News	Virginia	23602	—
Clinical Trial Site	Norfolk	Virginia	23502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01180790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 30, 2023 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01180790 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →